Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$290.22
neg -6.97
-2.35%
Today's Range: 289.48 - 299.89 | BIIB Avg Daily Volume: 1,541,900
Last Update: 12/05/16 - 4:00 PM EST
Volume: 1,832,848
YTD Performance: -3.45%
Open: $298.94
Previous Close: $297.19
52 Week Range: $223.02 - $338.51
Oustanding Shares: 217,574,479
Market Cap: 64,354,179,399
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 9 8 9
Moderate Buy 1 1 1 1
Hold 4 6 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.78 1.83 1.70
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 20.09
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
20.09 18.20 0.00
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.35% 4.29% 1.65%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
EBITDA 4.28B
Revenue 9.42B
Average Earnings Estimates
Qtr (12/16) Qtr (03/17) FY (12/16) FY (12/17)
Average Estimate $5.00 $4.97 $20.22 $20.80
Number of Analysts 18 12 17 18
High Estimate $5.50 $5.39 $20.69 $23.31
Low Estimate $4.68 $4.63 $19.86 $19.17
Prior Year $4.50 $4.79 $17.01 $20.22
Growth Rate (Year over Year) 11.06% 3.67% 18.85% 2.87%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Bret Jensen

 | Nov 25, 2016 | 10:00 AM EST
The worst appears to be over for this sector; we could see big growth ahead.
RMPIA
By

Jim Cramer

 | Nov 21, 2016 | 4:15 PM EST
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
RMPIA
By

Guy Ortmann

 | Nov 21, 2016 | 1:27 PM EST
The bullish side dominates, with consumer cyclicals and energy names most prevalent.
RMPIA
By

Bret Jensen

 | Nov 18, 2016 | 10:00 AM EST
With the election resolved, biotech could be ripe for consolidation.
RMPIA

bullishBiogen upgraded at Piper

Nov 7, 2016 | 7:22 AM EST
BIIB was upgraded from Neutral to Overweight, Piper Jaffray said. $335 price target. Valuation is reasonable, given opportunities in Alzheimer's and SMA.
RMPIA
By

Timothy Collins

 | Sep 6, 2016 | 11:21 AM EDT
Check out this biotech ETF, and Biogen, for plays on any recovery.
RMPIA

bearishBiogen downgraded at Jefferies

Sep 6, 2016 | 7:02 AM EDT
BIIB was downgraded to Hold, Jefferies said. Valuation call, based on a $323 price target.
RMPIA
By

Jim Cramer

 | Aug 29, 2016 | 6:00 AM EDT
The leadership is quite stark.
RMPIA
By

Bret Jensen

 | Aug 22, 2016 | 10:31 AM EDT
Las Vegas Sands (LVS) continues to show strength after Bank of America/Merrill Lynch put out an optimistic note this morning about Macau gambling. Energy is weak in early trading. Oil has drifted back down to around $47 a barrel following its recent roughly 20% rally.
RMPIA
By

Bret Jensen

 | Aug 22, 2016 | 7:54 AM EDT
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week.
BC is moving well today.  Shares are up over 3.5% on fairly heavy trade and are tradi...
Markets taking the latest rejection of the status quo in Italy in stride as the reforms we...
Merck continues to retreat from November's failed breakout.  Back on 9th and 10th of ...
Trifecta Stocks name Disney is bumping up to the 100 area hereon some good turnover and bu...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.